| Identification | Back Directory | [Name]
Secukinumab | [CAS]
1229022-83-6 | [Synonyms]
AIN457
AIN-457
AIN 457
Secukinumab
Secukinumab (anti-IL-17A)
Research Grade Secukinumab(DHH28802) | [MDL Number]
MFCD01092388 |
| Hazard Information | Back Directory | [Clinical Use]
Human IgG1/κ monoclonal antibody:
Treatment of moderate to severe plaque psoriasis,
psoriatic arthritis, ankylosing spondylitis | [Drug interactions]
Potentially hazardous interactions with other drugs
Vaccines: risk of generalised infections with live
vaccines - avoid. | [Metabolism]
The majority of IgG elimination occurs via intracellular
catabolism, following fluid-phase or receptor mediated
endocytosis. |
|
|